These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 21129465)
1. Plume temperature emitted from metered dose inhalers. Brambilla G; Church T; Lewis D; Meakin B Int J Pharm; 2011 Feb; 405(1-2):9-15. PubMed ID: 21129465 [TBL] [Abstract][Full Text] [Related]
2. Development and performance of a new hydrofluoroalkane (HFA 134a)-based metered dose inhaler (MDI) of salmeterol. Peyron ID; Britto IL; Benissan LB; Tardieu BZ Respir Med; 2005 Apr; 99 Suppl A():S20-30. PubMed ID: 15777605 [TBL] [Abstract][Full Text] [Related]
6. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology. Kleinstreuer C; Shi H; Zhang Z J Aerosol Med; 2007; 20(3):294-309. PubMed ID: 17894536 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Fireman P; Prenner BM; Vincken W; Demedts M; Mol SJ; Cohen RM Ann Allergy Asthma Immunol; 2001 May; 86(5):557-65. PubMed ID: 11379808 [TBL] [Abstract][Full Text] [Related]
8. Factors affecting the efficiency of aerosol therapy with pressurised metered-dose inhalers through plastic spacers. Chuffart AA; Sennhauser FH; Wildhaber JH; Swiss Med Wkly; 2001 Jan; 131(1-2):14-8. PubMed ID: 11205181 [TBL] [Abstract][Full Text] [Related]
9. Clinical comparability between the CFC and HFA budesonide pressurised metered-dose inhalers in paediatric patients with asthma: a randomised controlled trial. Escribano A; Tutuncu A; Löhr I; Carlholm M; Polanowski T Curr Med Res Opin; 2006 Jun; 22(6):1085-92. PubMed ID: 16846541 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the systemic pharmacodynamic effects and pharmacokinetics of salmeterol delivered by CFC propellant and non-CFC propellant metered dose inhalers in healthy subjects. Kempsford R; Handel M; Mehta R; De Silva M; Daley-Yates P Respir Med; 2005 Apr; 99 Suppl A():S11-9. PubMed ID: 15777604 [TBL] [Abstract][Full Text] [Related]
12. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications. Boccuzzi SJ; Wogen J; Roehm JB Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983 [TBL] [Abstract][Full Text] [Related]
13. Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers. Doub WH; Shah V; Limb S; Guo C; Liu X; Ngo D J Pharm Sci; 2014 Nov; 103(11):3648-3656. PubMed ID: 25228114 [TBL] [Abstract][Full Text] [Related]
14. Influence of propellant composition on drug delivery from a pressurized metered-dose inhaler. Williams RO; Repka M; Liu J Drug Dev Ind Pharm; 1998 Aug; 24(8):763-70. PubMed ID: 9876524 [TBL] [Abstract][Full Text] [Related]
15. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Gabrio BJ; Stein SW; Velasquez DJ Int J Pharm; 1999 Sep; 186(1):3-12. PubMed ID: 10469919 [TBL] [Abstract][Full Text] [Related]
17. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. Ross DL; Gabrio BJ J Aerosol Med; 1999; 12(3):151-60. PubMed ID: 10623331 [TBL] [Abstract][Full Text] [Related]
18. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica. Cheng YS; Fu CS; Yazzie D; Zhou Y J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657 [TBL] [Abstract][Full Text] [Related]
19. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related]
20. The technical transition to CFC-free inhalers. Tansey I Br J Clin Pract Suppl; 1997 May; 89():22-7. PubMed ID: 9519509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]